t(16;16)(p13;q22) CBFB-MYH11. Screening for mutations of c-KIT was performed on cDNA by PCR amplification followed by Sanger sequencing of exons 8 and 17 or analysis by the Genescan and Genemapper software (Applied Biosystems Inc., Foster City, CA, USA) for exon 11. The primers used are listed in Supplementary  Table 1S . Denaturing, annealing and extension steps were performed at 95 1C for 30 s, 60 1C for 30 s, 72 1C for 30 s, respectively, for a total of 40 cycles on a thermocycler. PCR products were resolved on a 2% agarose gel. After visual confirmation of amplification, 4 ml of PCR products of exon 8 or 17 were purified with a mixture of 0.5 ml Exonuclease I and 1 ml of FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific, Milan, Italy) and analyzed by bidirectional sequencing on an ABI310 sequencer, using the BigDye terminator kit v3.1 (Applied Biosystems Inc.). The prognostic impact of a c-KIT mutation was assessed analyzing overall and event-free survival (OS, EFS) probabilities; the log-rank (Mantel-Cox) test was employed to detect differences between subgroups.
The screening showed that 5/61 (8%) t(8;21) patients were positive for a point mutation at either codon D816 or N822, affecting the activation loop of the kinase; 1/61 for internal tandem duplication at exon 11 and 9/61 (15%) for small deletions and/or insertions of variable size in the extracellular portion of the receptor (exon 8). Overall, we found that, among the 61 patients harboring the RUNX1-RUNX1T1 translocation, 15 were mutated for c-KIT (25%). In the cohort of CBFB-MYH11-rearranged patients, we documented a lower incidence of c-KIT mutations, being found in five patients out of the 27 analyzed (18.5%) ( Table 1 ). In inv(16)/t(16;16)-rearranged patients, the mutations were found predominantly in exon 8 (4/5), with just one patient harboring D816V; none had internal tandem duplication. Interestingly, RUNX1-RUNX1T1-rearranged patients and c-KITmutated patients had a significantly worse 4-year OS (51.9%; s.e. 14.3%) and EFS (51.8%; s.e. ¼ 14.3%) than patients with isolated t(8;21) (OS ¼ 89.6%, s.e. ¼ 6.9%, P ¼ 0.0002; Figure 1a ; EFS ¼ 78.3%, Abbreviations: F, female; ITD, internal tandem duplication; M, male; nt, nucleotides; OS, overall survival; RFS, relapse-free survival; WBC, white blood cell.
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s.e. ¼ 6.4%, P ¼ 0.0176; Figure 1b) , suggesting that c-KIT mutations might contribute to the inferior outcome reported for this subgroup of AML, which has been considered at good prognosis by different collaborative international groups. We highlight that RUNX1-RUNX1T1-rearranged patients without c-KIT mutations reached the expected survival (90%) for this SR group. The number of c-KIT-mutated, CBFB-MYH11-rearranged patients was too small for permitting to find, if any, statistical differences in terms of outcome in comparison to patients who did not carry the c-KIT mutation. Noteworthy, there was no statistically significant difffrence between c-KIT-mutated and nonmutated CBF-rearranged patients in terms of the main clinical features (see also Supplementary Table 2S ).
The prognostic significance of a c-KIT mutation in other pediatric CBF-AML cohorts has been reported to be different in previously published studies. Goemans et al. 5 identified c-KIT aberrancies in 10/27 children (37%), with a higher incidence of mutation in inv(16) compared with t(8;21) (54.5% vs 31.3%). Shih et al. 6 detected abnormalities of c-KIT in 17/41 (41.4%) children with CBF-AML: 12/28 (43%) were mutated in RUNX1-RUNX1T1-rearranged children as compared with 5/13 (38.5%) in inv(16). Both studies did not find any statistical influence of a c-KIT mutation on patient outcome. In addition, Pollard et al. 4 analyzed the mutation status of 203 children with CBF-AML finding c-KIT mutations in 19/94 t(8;21) patients and in 19/71 carrying inv(16). Notwithstanding the large sample size, the results did not reach significance for survival parameters. These findings are in contrast with our data and with the data published by Shimada et al. 7 who screened 46 t(8;21) children for c-KIT mutations. Significant differences between patients with or without c-KIT mutations were observed in the 4-year OS (50.0% versus 97.4%, P ¼ 0.001), disease-free survival (37.5% versus 94.7%, Po0.001) and relapse rate (47.0% versus 2.7%, Po0.001). In view of our data on the incidence and the prognostic impact of c-KIT mutations, we believe that t(8;21) and inv(16)/t(16;16) patients should be analyzed separately. In particular, among our c-KIT-mutated patients who experienced relapse, we observed that five out of five t(8;21) patients were dead, whereas five out of the seven RUNX1-RUNX1T1-positive non c-KIT-mutated children who relapsed were rescued by second-line treatment. These findings provide the rationale for considering c-KIT mutations as an additional genetic marker to be taken into account in patient stratification.
The nature of c-KIT mutations offers an attractive target for tyrosine kinase inhibitors. c-KIT mutations are associated with a gain of function that induces receptor hyperactivation in response to SCF stimulation, and this leads to a loss of growth factor dependency, increased proliferation and resistance to apoptosis. 9 Notably, different drugs have been developed against tyrosine kinases. Imatinib has been demonstrated to be suitable for mutations at exon 8 and exon 17 involving specifically the codon N822, but not for mutations involving codon D816, which can be successfully targeted with other drugs, such as dasatinib and midostaurin. However, the utility of receptor tyrosine kinase inhibitors for patients with CBF-AML and c-KIT mutations remains to be further evaluated. Nowadays, the multistep model of leukemogenesis is widely accepted: class-II mutations affecting genes that impair hematopoietic differentiation, such as RUNX1-RUNTX1 and CBFB-MYH11, cooperate with class-I mutations involving genes, such as KIT, FLT3 and RAS, whose mutation leads to increased cell proliferation and survival. Expression of RUNX1 and CBF-b appears to be essential for the development of normal hematopoiesis, as knock out of these genes in animal models leads to lack of definitive hematopoiesis and embryonic animal death. 10 Nevertheless, in vitro and in vivo studies have shown that isolated CBF fusion transcripts were not sufficient to induce leukemogenesis, additional events being necessary for overt leukemia occurrence. [11] [12] [13] Recently, two different studies reported that patients with t(8;21) treated with a lipid formulation of daunorubicin during induction therapy had a better outcome than those treated with idarubicin, 14 and that a second induction course with high-dose cytarabine and mitoxantrone is beneficial for patients with t (8, 21) . 15 It remains to be proved whether the advantage of both these therapies mainly concentrates in patients harboring the c-KIT mutation.
In summary, we characterized the incidence of c-KIT mutations in CBF-rearranged patients treated with the AIEOP AML 2002/01 protocol; it was 25% and 18.5% for children carrying t(8;21) and inv(16)/ t(16;16), respectively. We document that the detection of a c-KIT mutation at diagnosis in t(8;21)-positive patients confers a detrimental prognostic impact. These patients might benefit from a targeted therapy with tyrosine kinase inhibitors. Letters to the Editor
